Background: Polyendocrine metabolic ovarian syndrome (PMOS), formerly referred to as polycystic ovary syndrome (PCOS), is among the most common endocrine disorders in women of reproductive age. Methods: An extensive literature search was done on Cochrane, PubMed, TRIP and Google Scholar. Pooled effect estimates were calculated using a fixed-effect model (I2<0 %) and a random-effects model was applied (I2>50 %). Result: The combination of metformin and liraglutide was associated with significantly lower fasting blood glucose level as compared to mono-therapy [MD]= -0.19 mmol/L, 95% CI: -0.33-0.06 mmol/l, Z=2.79, P=0.005, χ²=6.08, df=3, P=0.11, I2=0%). The combination of drugs significantly increased sex hormone binding globulin as compared to monotherapy [MD]= 7.89L, 95% CI 3.80-11.99, Z=3.78, P=0.0002, χ²=1.74, df=1, P=0.19, I2=42%). The pooled analysis demonstrated that metformin significantly reduced the risk of nausea as compared to the Metformin and liraglutide combination (RR=8.30 95% CI: 2.64, 26.10, Z=3.62, P=0.0003, χ²=0.43, df=2, p=0.80, I2 =0%). Conclusion: The combination of liraglutide and metformin was found to be advantageous over metformin in monotherapy, with respect to improving the patient’s glycaemic control by inducing a significant reduction in the fasting blood glucose level as compared to monotherapy. The combination therapy also significantly increased sex hormone binding globulin, such hormonal control is an underpinning facet in the treatment of PMOS and therefore this finding advocates for the use of metformin and liraglutide in combination.
BBMs play a crucial role in combating Alzheimer’s disease and should be prioritized. To embed them in routine primary care, it is essential for governments and health organizations to finance evaluations in varied demographics, establish coverage policies, and integrate BBMs into existing workflows. Their accuracy, comparable to traditional invasive methods, enables early detection of AD, allowing for lifestyle adjustments and therapies that may hinder or delay disease progression. For patients, this means gaining a sense of control, meeting their needs, and moving forward without the burden of an uncertain diagnosis. This is not merely a transient trend; embracing BBMs could fundamentally alter the perception of aging in a future where Alzheimer’s disease diminishes in prominence.
Background: The main objective of this study was to determine the prevalence and academic predictive factors of burnout among medical undergraduate students attending Sir Seewoosagur Ramgoolam Medical College (SSRMC), Mauritius. Methods: A mixed-methods cross-sectional study was conducted among medical students studying at SSRMC between December 2025 and February 2026. Results: A total of 232 students participated in the quantitative study with majority being females (147, 63.4%). The Burnout Assessment Tool-Student Version reported an average level of burnout (49.57%) with the exhaustion component being the most significant (mean = 3.45 ± 0.883). Descriptive analysis of the predictive factors showed that academic self-perception had the highest mean (3.266 ± 0.710) and perceptions of workload was identified as the only statistically significant predictor (β = -0.315, t = -3.968, p <0.001). A notable gender disparity was seen with female students demonstrating higher total burnout levels (mean difference 0.29). Qualitative analysis of twenty interviewees focused on identifying the understanding, causes, impact, coping strategies and recommendations for burnout, which revealed tedious academic and examination schedules among the important contributing factors for this phenomenon. Conclusion: Burnout was highly prevalent among medical students, especially females, with academic workload being the most significant predictor.
Cardiovascular disease is the leading cause of mortality worldwide, claiming the lives of roughly 18 million individuals annually. MicroRNAs have been found to have a highly active role in the pathogenesis and progression of Cardiovascular disease. The top 10 studied MicroRNAs in cardiovascular disease are namely miR-1, miR-208, miR-21, miR-29, miR-126, miR-145, miR-133, miR-155, miR-30 and miR-499.The potential and the development of the use of MicroRNAs will open up a new frontier in molecular cardiology and will further expand the frontier of precision medicine. MicroRNAs are almost limitless in their capabilities therapeutically, as they can be mimicked or inhibited, depending on their specific mechanism. It is evident that microRNAs will be a vital tool that both saves a countless number of lives as well as aids in reducing the mortality and morbidity in patients suffering from chronic diseases, most specifically in cardiovascular diseases. Their clinical and therapeutic potential are almost limitless and will someday be a mainstay in patient management and treatment.
Background:Obesity and type 2 diabetes are significant global health problems. Tirzepatide, a dual GIP/GLP-1 receptor agonist, and semaglutide, a selective GLP-1 receptor agonist, are the top incretin therapy options, but their relative effectiveness and safety based on direct head- to -head studies have not been pooled. This meta-analysis aims to compare the efficacy and safety of tirzepatide versus semaglutide. Methods:PubMed, Embase, and ScienceDirect were searched up to February 2026 to find the articles. Mean differences (MD) and risk ratios (RR) were pooled using a random-effects model and heterogeneity was measured using I2. Results:Three studies were included. Tirzepatide caused significantly greater reduction in weight than semaglutide (pooled MD = -5.19 kg, 95% CI: -7.96 to -2.42; p = 0.0002; I2 = 88.5%) and increased the possibility of ≥10% weight loss (pooled RR = 1.50, 95% CI: 1.15-1.96; p = 0.0069; I2 = 86.3%). No significant difference was observed in any adverse events, or gastrointestinal events; however, there was a greater number of serious adverse events with tirzepatide (RR = 1.83, 95% CI: 1.18-2.85; p = 0.007). Conclusion:Tirzepatide can provide better weight loss than semaglutide with relatively similar safety, except that serious adverse events were more frequent. Studies with long follow-up are required to confirm the cardiovascular safety.
